In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.    Read More

FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."    Read More

I had a visit on Power Lunch today and we talked about the effect on the health care stocks depending on who wins the White House. In general, pharmaceutical companies do well when they have a new product pipeline of innovative products that allow them to command high prices.    Read More

The week began with a flashback to the credit crisis.  It ended with figures showing the fastest inflation in six months and the lowest consumer-sentiment reading in 28 years.  Along the way, as the stock market ebbed and flowed, CNBC guests assembled a collective portfolio that was heavy on technology, energy, and global exposure.   Read More

Robert Zagunis says investors should put their money into shares of diversified international companies: "where the action is."   Read More

Sometimes a deal from hell can become one hell of a deal. Following are three takeover stories that could be worth a trade.   Read More

After last week's massive tumble in the Dow, Dan Genter of RNC Genter Capital Management and Jill Evans of Alpine Funds say a company's dividends deserve as much attention -- at least -- as total returns.   Read More

After last week's massive tumble in the Dow, Dan Genter of RNC Genter Capital Management and Jill Evans of Alpine Funds say a company's dividends deserve as much attention -- at least -- as total returns.   Read More

Michael Maslansky of Luntz, Maslansky Strategic Research just went on the air with me. His company polled 1,000 people online and asked them various questions about the Olympics. Here is the most important question. How much more or less likely are you to buy a product...    Read More

Time to face the foul facts, America. To profit amid our economic pain you may have no choice but to dive headlong into the muck.   Read More